Aspire Biopharma Holdings, Inc. SEC 10-Q Report
Aspire Biopharma Holdings, Inc. released its Form 10-Q report for Q3, highlighting minimal revenue of $1,941 and a significant net loss of $19,773,114. The company focuses on sublingual delivery mechanisms for drugs and supplements, with most sales in the USA. Future plans include expanding sales, marketing, and R&D, requiring additional financing.
Aspire Biopharma Holdings, Inc., a company focused on developing and marketing innovative sublingual delivery mechanisms for known drugs and supplements, has released its Form 10-Q report for the third quarter. The report provides a detailed overview of the company's financial performance and business operations, reflecting its early-stage status and ongoing efforts to expand its market presence.
Financial Highlights
- Net Revenue: $1,941 - The company reported minimal revenue for the period, indicating early-stage operations.
- Gross Profit: $884 - Reflects the initial stages of product sales with limited profitability.
- Loss from Operations: $(17,501,867) - The company experienced significant operating losses, primarily due to high general and administrative expenses, including stock-based compensation.
- Net Loss: $(19,773,114) - The substantial net loss is attributed to high operating expenses and interest expenses.
- Basic and diluted net loss per share of Common Stock: $(0.43) - Reflects the impact of the net loss on shareholders.
Business Highlights
- Revenue Segments: The company reported revenue from nutraceutical products, with sales primarily occurring in the USA and a small portion in Canada. This indicates a focus on the North American market for its product distribution.
- Geographical Performance: The majority of sales were concentrated in the USA, accounting for $1,901 of the total revenue, with Canada contributing $40. This suggests a strong domestic market presence with limited international reach.
- New Product Launches: Aspire Biopharma Holdings, Inc. is focused on developing and marketing disruptive technology for novel sublingual delivery mechanisms, initially targeting known drugs and supplements such as aspirin and caffeine products. This indicates ongoing efforts to innovate within the pharmaceutical and supplements industry.
- Future Outlook: The company plans to continue its focus on expanding sales and marketing efforts, as well as research and development activities. However, it acknowledges the need for additional financing to support these initiatives, which may involve raising capital through equity issuances.
SEC Filing: Aspire Biopharma Holdings, Inc. [ ASBP ] - 10-Q - Nov. 14, 2025
